Previous 10 | Next 10 |
Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers Progress towards IND filing for KIN-2787, our RAF inhibitor candidate, in the first half of 2021 and initiating a Phase 1 clinical trial later in the year...
Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...
Kinnate Biopharma (KNTE) to be added to the Russell 2000® Index after US equity markets close on March 19, 2021. “Kinnate’s inclusion in the Russell 2000 Index marks an exciting milestone following our successful IPO in December 2020 and is a testament ...
SAN FRANCISCO and SAN DIEGO, March 19, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, toda...
The following slide deck was published by Kinnate Biopharma Inc. in conjunction with this event. For further details see: Kinnate Biopharma (KNTE) Investor Presentation - Slideshow
SAN FRANCISCO and SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today...
Point Roberts, WA and Delta, BC - January 15, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch in Biotech, Tech and Agriculture. Today's stocks have been added to o...
As the IPO quiet period ends, Kinnate Biopharma (KNTE) is enticing bullish views on Wall Street. The analysts from SVB Leerink, Piper Sandler, Wedbush, and Goldman Sachs have all weighed in with buy ratings for Kinnate. The target price ranges from $48 - $60, an upside of 26.3% - 57...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Expectations are coming in for 2021. Despite the strong recent gains and record valuations, analysts and investors are expecting even more upside based on "the new normal". The IPO market has proven to be an extremely valuable indicator for future returns. Investors are clearly missin...
News, Short Squeeze, Breakout and More Instantly...
Kinnate Biopharma Inc. Company Name:
KNTE Stock Symbol:
NASDAQ Market:
Kinnate Biopharma Inc. Website:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced th...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...